Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.012
Neutral
RSI(14)
32.860
Neutral
STOCH(KDJ)(9,3,3)
38.123
Sell
ATR(14)
0.028
Low Volatility
CCI(14)
-152.743
Sell
Williams %R
76.205
Sell
TRIX(12,20)
-1.387
Sell
StochRSI(14)
0.000
Sell
Search
Scinai Immunotherapeutics Ltd
SCNIAdd to Watchlist
0.244USD
+0.014+6.00%
Market hours （ET）Quotes delayed by 15 min
845.55KMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+6.00%
5 Days
-2.40%
1 Month
-2.87%
6 Months
-77.63%
Year to Date
-65.76%
1 Year
-88.17%
Key Figures
0.230Open
0.270High
20.79KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.60%Turnover Ratio
0.230Prev. Close
0.230Low
3.84KTurnover
0.18P/E Static
0.34P/B
0.00%Div Yield TTM
-66.26%ROA
6.18052wk High
1.17Volume Ratio
4.80MNet Profit
3.47MShares
-3.5600EPS TTM
2.09Beta
-243.39%ROE
0.40752wk Low
17.39%Amplitude
-228.63%Gross Margin
845.55KMarket Cap
-1.37Reward/Risk
6.11%Risk Rate
TradingKey Stock Score of Scinai Immunotherapeutics Ltd
Currency: USD Updated: 2026-07-24Key Insights
Scinai Immunotherapeutics Ltd's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 210 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Scinai Immunotherapeutics Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Scinai Immunotherapeutics Ltd Highlights
StrengthsRisks
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.31M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.31M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -0.06, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 179.71K shares, increasing 15.87% quarter-over-quarter.
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Scinai Immunotherapeutics Ltd News
More news coming soon, stay tuned...
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.244
Sell
MA10
0.247
Sell
MA20
0.255
Sell
MA50
0.350
Sell
MA100
0.496
Sell
MA200
0.757
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Scinai Immunotherapeutics Ltd Info
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Ticker SymbolSCNI
CompanyScinai Immunotherapeutics Ltd
CEOReichman (Amir)
Websitehttps://www.scinai.com/
Shareholders
Related Instruments
+0.19%
+1.60%
+1.91%
+0.53%
+0.76%
+1.72%
+0.98%
+1.98%
+2.34%
+0.98%
+1.86%
+1.48%
+2.34%
+2.32%
+1.62%
0.00%
+2.63%
-1.57%
+2.05%
+0.74%Popular Instruments
52205.900
+305.900 (+0.59%)
28006.600
-143.800 (-0.51%)
7419.300
+11.200 (+0.15%)
15108.000
+160.000 (+1.07%)
63946.000
-273.000 (-0.42%)
6311.700
+47.200 (+0.75%)
82.865
-7.178 (-7.97%)
337.300
+4.280 (+1.29%)
198.840
-8.000 (-3.87%)
4073.750
+21.400 (+0.53%)
FAQs
What is the current price of Scinai Immunotherapeutics Ltd (SCNI)?
The current price of Scinai Immunotherapeutics Ltd (SCNI) is 0.23.
What is the symbol of Scinai Immunotherapeutics Ltd?
The ticker symbol of Scinai Immunotherapeutics Ltd is SCNI.
What is the 52-week high of Scinai Immunotherapeutics Ltd?
The 52-week high of Scinai Immunotherapeutics Ltd is 6.18.
What is the 52-week low of Scinai Immunotherapeutics Ltd?
The 52-week low of Scinai Immunotherapeutics Ltd is 0.41.
What is the market capitalization of Scinai Immunotherapeutics Ltd?
The market capitalization of Scinai Immunotherapeutics Ltd is 1.19M.
What is the Earnings Per Share (EPS TTM) of Scinai Immunotherapeutics Ltd (SCNI)?
The Earnings Per Share (EPS TTM) of Scinai Immunotherapeutics Ltd (SCNI) is -3.56.